Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8843544 | 0.81 | ITGA4 (0.46) | MEN1KMT2ATACR1HPGDALDH1A1 | |
| SCHEMBL2789419 | 0.80 | KMT2A (0.52) | MEN1KMT2ATACR1HPGDSMN1; SMN2 | |
| SCHEMBL3745591 | 0.73 | RAB9A (0.49) | MEN1KMT2AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL9367070 | 0.71 | KDM4E (0.46) | MEN1KMT2AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL23317870 | 0.70 | CHRM2 (0.48) | MEN1KMT2AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL27984494 | 0.69 | OPRM1 (0.42) | MEN1KMT2ATACR1HPGDSMN1; SMN2 | |
| SCHEMBL28836843 | 0.69 | OPRK1 (0.55) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4848163 | 0.68 | OPRD1 (0.56) | — | |
| SCHEMBL11969357 | 0.68 | OPRD1 (0.56) | — | |
| SCHEMBL8545031 | 0.68 | ALDH1A1 (0.61) | MEN1KMT2AHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067535-B2 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20040097548-A1 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | TANABE SEIYAKI CO., LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1323713-A1 | 5-PHENYLBENZYLAMINE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND INTERMEDIATES FOR THEIR SYNTHESIS | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097548-A1 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | CYP1B1, MAOB, HTR1B | MEN1 1926/4885KMT2A 572/4885TACR1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.